Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

liver solid financial results and to advance our late-stage pipeline, with four regulatory filings completed this year alone," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We are successfully executing our strategy which will enable us to return to growth after 2014 by bringing to the market new medicines that make a real difference for patients."

"We remain committed to our innovation strategy and believe it will drive growth and expand margins post-2014," added Derica Rice, Lilly executive vice president, global services and chief financial officer. "We will also return substantial cash to shareholders by maintaining our dividend at least at its current level and by repurchasing shares under our recently-authorized $5 billion program."

Key Events Over the Last Three Months

  • Dulaglutide was submitted for regulatory review in both the U.S. and Europe as a potential treatment for type 2 diabetes.
  • The U.S. rolling submission was completed for ramucirumab as a single-agent treatment for patients with advanced gastric cancer who have had disease progression after initial chemotherapy. A submission for ramucirumab for the same indication was also made in Europe.
  • Top-line results were announced from two global Phase III studies of ramucirumab. In the first study, ramucirumab, in combination with paclitaxel in patients with advanced gastric cancer, met its primary endpoint of improved overall survival and a secondary endpoint of improved progression-free survival. A second study of ramucirumab in women with locally recurrent or metastatic breast cancer did not meet its primary endpoint of progression-free survival.
  • A recently completed Phase III study for necitumumab met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
    2. Lilly Declares Fourth-Quarter 2013 Dividend
    3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
    4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
    5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
    6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
    7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
    8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
    9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
    10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
    11. Lilly Reports Second-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
    (Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
    (Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
    Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
    ... Nov. 1, 2010 LitePoint Corporation, the leader in ... Health Alliance, along with other technology leaders. ... of personal healthcare and to establish a system of ... for all people. "Wireless will be ...
    ... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
    Cached Medicine Technology:LitePoint Joins Continua Health Alliance 2China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2
    (Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
    (Date:12/17/2014)... Amy Norton HealthDay ... Yoga has long been believed to improve overall health, but ... also help the heart, a new review finds. In ... such as brisk walking, said lead researcher Paula Chu, a ... The review, of 37 clinical trials, found that people ...
    (Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic ... JM Ocean Avenue has secured exclusive benefit to the ... system. JM Ocean Avenue is a direct sales ... Avenue and JM International, with partial ownership coming from ... company. , “After nearly 2 decades of servicing the ...
    (Date:12/15/2014)... MD (PRWEB) December 15, 2014 ... services today released “ Social Media Cheat Sheets ,” ... a community that drives results on the top ten ... marketing program. It helps drive awareness, engagement, and customer ... For marketers to make an impact on new networks ...
    (Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
    Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
    ... researchers from the University at Buffalo School of Dental ... X-ray// may serve as an accurate early-warning system of ... ,The study was ushered in a population with a ... us closer to the use of panoramic dental radiographs ...
    ... that people become addicted to nicotine by smoking regularly over ... be more disturbing. According to a Canadian study, young people ... no more than a few cigarettes a month. ,Using ... young people in their first year of high school to ...
    ... know when someone who talks about suicide will actually ... which depressed patients need protection.Now American scientists believe that// ... blood test that checks glands controlling the stress hormone ... to the mental turmoil that leads people to take ...
    ... report they have identified a genetic defect that causes a ... bone, a finding that may lead to treatments for osteoporosis. ... mineral center at Hopkins University, the new finding will help ... make new bone cells as people age.// ,Later, ...
    ... food poisonings aren't going away, despite the efforts of ... imported foods and bacteria develop in new forms, according ... The bacteria Listeria monocytogenes are so common in the ... of them. ,The scientists also say the ...
    ... for Disease Control and Prevention (CDC) say that tobacco ... caries and tobacco use data from more than// 13,000 ... between the two types of spit tobacco, also called ... cigarettes, pipes, and cigars. Spit tobacco comes in two ...
    Cached Medicine News:Health News:Mutation connected to Osteoporosis 2
    ... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
    The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
    Galilean Loupes...
    ... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
    Medicine Products: